Conversion From Twice-Daily Tacrolimus Capsules to Once-Daily Extended-Release Tacrolimus (LCPT): A Phase 2 Trial of Stable Renal Transplant Recipients
Open accessThe DOI matches its Crossref record, with a small difference in title or year; 25 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: LCP-Tacro is an extended-release formulation of tacrolimus designed for once-daily dosing. Phase 1 studies demonstrated greater bioavailability to twice-daily tacrolimus capsules and no new safety concerns. METHODS: In this phase 2 study, adult stable kidney transplant patients on tacrolimus capsules (Prograf) twice-daily were converted to tacrolimus tablets (LCP-Tacro) once-daily; patients continued on LCP-Tacro once-daily for days 8 to 21; trough levels were to be maintained between 5 and 15 ng/mL; 24-hr pharmacokinetic assessments were done on days 7 (baseline pre-switch), 14, and 21. RESULTS: Forty-seven patients completed LCP-Tacro dosing per protocol. The mean conversion ratio was 0.71. Pharmacokinetic data demonstrated consistent exposure (AUC) at the lower conversion dose. C(max) (P = 0.0001), C(max)/C(min) ratio (P < 0.001), percent fluctuation (P < 0.0001), and swing (P = 0.0004) were significantly lower and T(max) significantly (P < 0.001) longer for LCP-Tacro versus Prograf. AUC24 and C(min) correlation coefficients after 7 and 14 days of therapy were 0.86 or more, demonstrating a robust correlation between LCP-Tacro tacrolimus exposure and trough levels. There were three serious adverse events; none were related to study drug and all were resolved. CONCLUSIONS: Stable kidney transplant patients can be safely converted from Prograf twice-daily to LCP-Tacro. The greater bioavailability of LCP-Tacro allows for once-daily dosing and similar (AUC) exposure at a dose approximately 30% less than the total daily dose of Prograf. LCP-Tacro displays flatter kinetics characterized by significantly lower peak-trough fluctuations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although exhibiting prolonged absorption and multicompartmental pharmacokinetics, t1/2eff has not previously been explored for tacrolimus from LCPT.6,10”
From Evaluation of Effective Half-Life and Its Impact on Time to Steady State for Oral MeltDose Tacrolimus (LCPT) in De Novo Kidney Transplant Recipients (2025) · cites this paper as [6]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“LCPT presents a proprietary MeltDose technology that enhances oral bioavailability through a process known as “controlled agglomeration”.6,7”
From Evaluation of Effective Half-Life and Its Impact on Time to Steady State for Oral MeltDose Tacrolimus (LCPT) in De Novo Kidney Transplant Recipients (2025) · cites this paper as [6]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The current study, which is the first to estimate the t1/2z for LCPT in adult kidney transplant recipients, approximated t1/2z at 20 hours compared with previous studies in healthy volunteers, where t1/2z estimates were reported to be approximately 31 hours.6,10”
From Evaluation of Effective Half-Life and Its Impact on Time to Steady State for Oral MeltDose Tacrolimus (LCPT) in De Novo Kidney Transplant Recipients (2025) · cites this paper as [6]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A systematic review of the associations between dose regimens and medication compliance
Claxton, A. J., Cramer, J., & Pierce, C. (2001) · Clinical Therapeutics · doi:10.1016/s0149-2918(01)80109-0 · Cited by 2,388
Genetic contribution to variable human CYP3A-mediated metabolism
Lamba, J. K., Lin, Y. S., Schuetz, E. G., & Thummel, K. E. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00066-2 · Cited by 990 · cited 1×
“This may partially account for lower troughs and higher dose requirements of tacrolimus among blacks (16).”
BackgroundThe Effect of Prescribed Daily Dose Frequency on Patient Medication Compliance
Eisen, S. A. (1990) · Archives of Internal Medicine · doi:10.1001/archinte.150.9.1881 · Cited by 817
Interventions to Enhance Medication Adherence in Chronic Medical Conditions: A Systematic Review
Kripalani, S., Yao, X., & Haynes, R. B. (2007) · Archives of Internal Medicine · doi:10.1001/archinte.167.6.540 · Cited by 810 · cited 1×
“In a review of medication adherence in chronic conditions, the most effective interventions appear to be those that simplify dosing demands (27, 28).”
BackgroundWallemacq, P., Armstrong, V. W., Brunet, M., Haufroid, V., Holt, D. W., Johnston, A., Kuypers, D., Meur, Y. L., Marquet, P., Oellerich, M., et al. (2009) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e318198d092 · Cited by 468 · cited 2×
“tacrolimus trough blood concentrations are measured to ensure efficacy and safety (3).”
Background(2009) · PubMed · Cited by 359
Staatz, C. E., Goodman, L. K., & Tett, S. E. (2010) · Clinical Pharmacokinetics · doi:10.2165/11317550-000000000-00000 · Cited by 343
Staatz, C. E., Goodman, L. K., & Tett, S. E. (2010) · Clinical Pharmacokinetics · doi:10.2165/11317350-000000000-00000 · Cited by 336
Macphee, I. A. M., Fredericks, S., Tai, T., Syrris, P., Carter, N. D., Johnston, A., Goldberg, L., & Holt, D. W. (2002) · Transplantation · doi:10.1097/00007890-200212150-00002 · Cited by 315
OPTN/SRTR 2011 Annual Data Report: Kidney
Matas, A. J., Smith, J. M., Skeans, M. A., Lamb, K. E., Gustafson, S. K., Samana, C. J., Stewart, D. E., Snyder, J. J., Israni, A. K., & Kasiske, B. L. (2013) · American Journal of Transplantation · doi:10.1111/ajt.12019 · Cited by 308 · cited 2×
“Tacrolimus is one of the most widely used immunosuppression drugs in kidney transplantation (1).”
Background
Cited by
Tremblay, S., Nigro, V., Weinberg, J., Woodle, E. S., & Alloway, R. R. (2017) · American Journal of Transplantation · doi:10.1111/ajt.13935 · Cited by 171
“LCPT is also associated with less fluctuation between maximum (“peak”) exposure and trough and with a lower peak exposure level (18).”
BackgroundResultInfluentialSelf-citationNelson, J., Alvey, N., Bowman, L., Schulte, J., Segovia, M. C., McDermott, J., Te, H. S., Kapila, N., Levine, D. J., Gottlieb, R. L., et al. (2022) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2716 · Cited by 130
Langone, A., Steinberg, S. M., Gedaly, R., Chan, L. K., Shah, T., Sethi, K. D., Nigro, V., Morgan, J. C., & STRATO Investigators (2015) · Clinical Transplantation · doi:10.1111/ctr.12581 · Cited by 119
“The PK profile of LCP-Tacro reveals a reduction in the peak-to-trough ratio and Cmax yet prolongs the Tmax of LCP-Tacro compared to twice-daily tacrolimus (18, 22).”
BackgroundRostaing, L. P. E., Bunnapradist, S., Grinyo, J. M., Ciechanowski, K., Denny, J. E., Junior, H. T. S., Budde, K., Denny, J. E., Kulkarni, S., Hricik, D. E., et al. (2015) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2015.10.024 · Cited by 115
Self-citationWhalen, H. R., Glen, J. A., Harkins, V., Stevens, K., Jardine, A. G., Geddes, C., & Clancy, M. J. (2016) · Transplantation · doi:10.1097/tp.0000000000001129 · Cited by 105
Metadata
- Authors
- Gaber, A. O., Alloway, R. R., Bodziak, K., Kaplan, B., & Bunnapradist, S.
- Affiliations
- Houston Methodist (US)
- Christ Hospital (US)
- University of Oklahoma Health Sciences Center (US)
- University of Illinois Chicago (US)
- University of California, Los Angeles (US)
- Corresponding author
- Gaber, A. Osama
- Venue
- Transplantation
- Published
- 2013-07-27
- Volume
- 96
- Issue
- 2
- Pages
- 191-197
- ISSN
- 0041-1337 (ISSN-L)
- PMC
- PMC3723088
- OpenAlex
- W2089557861
- Cited by
- 100
- References
- 25
- Citations by year
- 2026: 2 · 2025: 9 · 2024: 7 · 2023: 12 · 2022: 3 · 2021: 11 · 2020: 9 · 2019: 7 · 2018: 4 · 2017: 10 · 2016: 9 · 2015: 12 · 2014: 5
- FWCI
- 6.34
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Transplantation (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Baylor University
- University of Cincinnati
- Veloxis Pharmaceuticals
- University of Illinois at Urbana-Champaign
- University of California, Los Angeles
- Baylor University Medical Center
- Topics
- Health Sciences › Medicine › Transplantation › Renal Transplantation Outcomes and Treatments
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Keywords
- tacrolimus, sustained-release formulation, once-daily dosing, kidney transplant recipients, pharmacokinetics, bioavailability, trough concentration, immunosuppression
- MeSH terms
- Adult, Biological Availability, Capsules, Delayed-Action Preparations, Drug Administration Schedule, Female, Humans, Immunosuppressive Agents, Male, Middle Aged, Prospective Studies, Kidney Transplantation, Tacrolimus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Conversion From Twice-Daily Tacrolimus Capsules to Once-Daily Extended-Release Tacrolimus (LCPT): A Phase 2 Trial of Stable Renal Transplant Recipients. https://app.cochat.ai/papers/10.1097/tp.0b013e3182962cc1
- The paper
- Gaber, A. O., Alloway, R. R., Bodziak, K., Kaplan, B., & Bunnapradist, S. (2013). Conversion From Twice-Daily Tacrolimus Capsules to Once-Daily Extended-Release Tacrolimus (LCPT): A Phase 2 Trial of Stable Renal Transplant Recipients. Transplantation. https://doi.org/10.1097/tp.0b013e3182962cc1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.


